{"type":"trials","record":{"id":41830,"source_id":"clinicaltrials-gov","external_id":"NCT03844074","title":"A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)","brief_summary":"This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.","overall_status":"Completed","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Outlook Therapeutics, Inc.","enrollment":61,"countries":["Australia"],"start_date":"2018-10-01","completion_date":"2020-08-13","last_update_date":"2025-03-19","source_url":"https://clinicaltrials.gov/study/NCT03844074","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":"ranibizumab","organization":"Outlook Therapeutics, Inc.","interventions":["bevacizumab","ranibizumab"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Proportion of subjects who gain 15 or more letters in the best corrected visual acuity (BCVA) score — Baseline, 11 mont…","Mean change in the best corrected visual acuity over time — Baseline, monthly to 11 months","Proportion of participants who gain at least 10 letters in the best corrected visual acuity score — Baseline, 11 months","Proportion of participants who gain at least 5 letters in the best corrected visual acuity score — Baseline, 11 months","Proportion of participants who lose fewer than 15 letters in the best corrected visual acuity score — Baseline, 11 mont…","Proportion of participants with visual-acuity Snellen equivalent of 20/200 or worse — Baseline, 11 months","Percentage of participants with ocular adverse events, non-ocular adverse events, grade 3 and above laboratory abnormal…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · DOUBLE","source_has_results":false},"controlled_terms":["Age-related Macular Degeneration","Neovascular Age-related Macular Degeneration","Wet Macular Degeneration","bevacizumab","ranibizumab"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct03844074","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2018-10-01 to 2020-08-13","comparator":"ranibizumab","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.878Z","intervention":["bevacizumab","ranibizumab"],"participants":61,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · DOUBLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Proportion of subjects who gain 15 or more letters in the best corrected visual acuity (BCVA) score — Baseline, 11 mont…","Mean change in the best corrected visual acuity over time — Baseline, monthly to 11 months","Proportion of participants who gain at least 10 letters in the best corrected visual acuity score — Baseline, 11 months","Proportion of participants who gain at least 5 letters in the best corrected visual acuity score — Baseline, 11 months","Proportion of participants who lose fewer than 15 letters in the best corrected visual acuity score — Baseline, 11 mont…","Proportion of participants with visual-acuity Snellen equivalent of 20/200 or worse — Baseline, 11 months","Percentage of participants with ocular adverse events, non-ocular adverse events, grade 3 and above laboratory abnormal…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41830","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}